Irritable bowel syndrome: The problem and the problem of treating it - Is there a role for probiotics?

Proceedings of the Nutrition Society

Volumn 73, Issue 4, 2014, Pages 470-476

  Santos, Antonieta R ^a   Whorwell, P J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Impact; Irritable bowel syndrome; Microbiota; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOATING; CONFERENCE PAPER; CONSTIPATION; CONSULTATION; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; GASTROINTESTINAL TRANSIT; HEALTH CARE PERSONNEL; HUMAN; IRRITABLE COLON; LETHARGY; LOW BACK PAIN; MICROFLORA; NAUSEA; PATHOPHYSIOLOGY; QUALITY OF LIFE; UROGENITAL TRACT DISEASE; GASTROINTESTINAL TRACT; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; TREATMENT OUTCOME;

GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PROBIOTICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84927701067     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665114000706     Document Type: Conference Paper

References (88)

1. Wilson S, Roberts L, Roalfe A et al. (2004) Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54, 495-502.
2. Spiegel BM (2009) The burden of IBS: looking at metrics. Curr Gastroenterol Rep 11, 265-269.
3. Maxion-Bergemann S, Thielecke F, Abel F et al. (2006) Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 24, 21-37.
4. Drossman DA, Corazziari E, Delvaux M et al. (2006) Rome III: The Functional Gastrointestinal Disorders, 3rd ed. McLean, Virginia, USA: Degnon Associated.
5. Agrawal A & Whorwell PJ (2006) Irritable bowel syndrome: diagnosis and management. Br Med J 332, 280-283.
6. Agrawal A & Whorwell PJ (2008) Review article: abdominal bloating and distension in functional gastrointestinal disorders-epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther 27, 2-10.
7. Whorwell PJ (2012) Unraveling functional abdominal bloating and distension: the role of thoraco-abdominal accommodation and a physical sign to aid its detection. Neurogastroenterol Motil 24, 301-304.
8. Whorwell PJ, McCallum M, Creed FH et al. (1986) Non-colonic features of irritable bowel syndrome. Gut 27, 37-40.
9. Guthrie E, Creed FH & Whorwell PJ (1987) Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration. Br Med J 295, 577-578.
10. Prior A & Whorwell PJ (1989) Gynaecological consultation in patients with the irritable bowel syndrome. Gut 30, 996-998.
11. Francis CY, Duffy JN, Whorwell PJ et al. (1997) High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci 42, 404-407.
12. Gralnek IM, Hays RD, Kilbourne A et al. (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119, 654-660.
13. Miller V, Hopkins L & Whorwell PJ (2004) Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2, 1064-1068.
14. Drossman DA, Camilleri M, Mayer EA et al. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123, 2108-2131.
15. Simren M, Barbara G, Flint HJ et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62, 159-176.
16. Whorwell PJ (2009) Do probiotics improve symptoms in patients with irritable bowel syndrome? Therap Adv Gastroenterol 2, 37-44.
17. Verdu EF, Bercik P & Collins SM (2009) Effect of pro-biotics on gastrointestinal function: evidence from animal models. Therap Adv Gastroenterol 2, 31-35.
18. Quigley EM & Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19, 166-172.
19. Hasler WL (2011) Traditional thoughts on the patho-physiology of irritable bowel syndrome. Gastroenterol Clin North Am 40, 21-43.
20. Agrawal A, Houghton LA, Morris J et al. (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29, 104-114.
21. Bartram HP, Scheppach W, Gerlach S et al. (1994) Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in health subjects? Am J Clin Nutr 59, 428-432.
22. Bouvier M, Meance S, Bouley C et al. (2001) Effects of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit time in healthy humans. Biosci Microflora 20, 43-48.
23. Holma R, Hongisto SM, Saxelin M et al. (2010) Constipation is relieved more by rye bread than wheat bread or laxatives without increased adverse gastrointestinal effects. J Nutr 140, 534-541.
24. Hongisto SM, Paajanen L, Saxelin M et al. (2006) A combination of fibre-rich rye bread and yoghurt containing Lactobacillus GG improves bowel function in women with self-reported constipation. Eur J Clin Nutr 60, 319-324.
25. Krammer HJ, Seggem HV, Schaumburg J et al. (2011) Effect of Lactobacillus casei Shirota on colonic transit time in patients with chronic constipation. Coloproctology 33, 109-113.
26. Malpeli A, González S, Vicentin D et al. (2012) Randomised, double-blind and placebo-controlled study of he effect of a synbiotic dairy product on orocecal transit time in healthy adult women. Nutr Hosp 27, 1314-1319.
27. Marteau P, Cuillerier E, Meance S et al. (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16, 587-593.
28. Rosenfeldt V, Paerregaard A, Nexmann CL et al. (2003) Faecal recovery, mucosal adhesion, gastrointestinal effects and tolerance of mixed cultures of potential prebio-tic lactobacilli. Microb Ecol Health Dis 15, 2-9.
29. Sairanen U, Piirainen L, Gråsten S et al. (2007) The effect of probiotic fermented milk and inulin on the functions and microecology of the intestine. J Dairy Res 74, 367-373.
30. Waller PA, Gopal PK, Leyer GJ et al. (2011) Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 46, 1057-1064.
31. Miller LE & Ouwehand AC (2013) Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 19, 4718-4725.
32. Ritchie J (1973) Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14, 125-132.
33. Azpiroz F, Bouin M, Camilleri M et al. (2007) Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 19, 62-88.
34. Johnson AC, Greenwood-Van Meerveld B & McRorie J (2011) Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 56, 3179-3186.
35. Agostini S, Goubern M, Tondereau V et al. (2012) A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 24, 376-e172.
36. Naliboff BD, Derbyshire SW, Munakata J et al. (2001) Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 63, 365-375.
37. Mertz H, Morgan V, Tanner G et al. (2000) Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 118, 842-848.
38. Tillisch K, Labus J, Kilpatrick L et al. (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144, 1394-1401, e1391-1394.
39. Spiller R & Lam C (2012) An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neuro-gastroenterol 18, 258-268.
40. Jalanka-Tuovinen J, Salojärvi J, Salonen A et al. (2013) Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut (Epublication ahead of print version).
41. Gwee KA, Leong YL, Graham C et al. (1999) The role of psychological and biological factors in postinfective gut dysfunction. Gut 44, 400-406.
42. Feng B, La JH, Schwartz ES et al. (2012) Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hyper-sensitivity in irritable bowel syndrome. Am J Psysiol Gastrointest Liver Physiol 302, G1085-G1098.
43. O'Mahony L, McCarthy J, Kelly P et al. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551.
44. Barbara G, Zecchi L, Barbaro R et al. (2012) Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol 46, Suppl., S52-S55.
45. Maxwell PR, Rink E, Kumar D et al. (2002) Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 97, 104-108.
46. Pimentel M, Kong Y & Park S (2003) Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol 98, 2700-2704.
47. Hempel S, Newberry SJ, Maher AR et al. (2012) Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. J Am Med Assoc 307, 1959-1969.
48. Heineman J, Bubenik S, McClave S et al. (2012) Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? Curr Gastroenterol Rep 14, 343-348.
49. Camilleri M, Madsen K, Spiller R et al. (2012) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24, 503-512.
50. Natividad JM & Verdu EF (2013) Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res 69, 42-51.
51. Madsen K, Cornish A, Soper P et al. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580-591.
52. Gonsalkorale WM, Cooper P, Cruickshanks PB et al. (2002) Hypnotherapy in irritable bowel syndrome: a large scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 97, 954-961.
53. Desbonnet L, Garrett L, Clarke G et al. (2008) The pro-biotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 43, 164-174.
54. Benton D, Williams C & Brown A (2007) Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 61, 355-361.
55. Messaoudi M, Lalonde R, Violle N et al. (2011) Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifido-bacterium longum R0175) in rats and human subjects. Br J Nutr 105, 755-764.
56. Menees SB, Maneerattannaporn M, Kim HM et al. (2012) The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107, 28-35. quiz 36.
57. Gade J & Thorn P (1989) Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 7, 23-26.
58. Halpern GM, Prindiville T, Blankenburg M et al. (1996) Treatment of irritable bowel syndrome with lacteol fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91, 1579-1585.
59. Nobaek S, Johansson ML, Molin G et al. (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95, 1231-1238.
60. Niedzielin K, Kordecki H & Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13, 1143-1147.
61. Whorwell PJ, Altringer L, Morel J et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101, 1581-1590.
62. Guyonnet D, Chassany O, Ducrotte P et al. (2007) Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26, 475-486.
63. Agrawal A, Houghton LA, Morris J et al. (2008) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29, 104-114.
64. Guglielmetti S, Mora D, Gschwender M et al. (2011) Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life, a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33, 1123-1132.
65. Dolin BJ (2009) Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 31, 655-659.
66. Kruis W, Chrubasik S, Boehm S et al. (2012) A doubleblind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 27, 467-474.
67. Kim HJ, Camilleri M, McKinzie S et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17, 895-904.
68. Kim HJ, Vazquez Roque MI, Camilleri M et al. (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17, 687-696.
69. Kim YG, Moon JT, Lee KM et al. (2006) The effects of probiotics on symptoms of irritable bowel syndrome. Korean J Gastroenterol 47, 413-419.
70. Kajander K, Hatakka K, Poussa T et al. (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22, 387-394.
71. Kajander K, Myllyluoma E, Rajilic-Stojanovic M et al. (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27, 48-57.
72. Williams E, Stimpson J, Wang D et al. (2009) Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 29, 97-103.
73. Sinn DH, Song JH, Kim HJ et al. (2008) Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 53, 2714-2718.
74. Enck P, Zimmermann K, Menke G et al. (2008) A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 20, 1103-1109.
75. Hong KS, Kang HW, Im JP et al. (2009) Effect of pro-biotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver 3, 101-107.
76. Sen S, Mullan MM, Parker TJ et al. (2002) Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47, 2615-2620.
77. O'Sullivan MA & O'Morain CA (2000) Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 32, 294-301.
78. Niv E, Naftali T, Hallak R et al. (2005) The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 24, 925-931.
79. Drouault-Holowacz S, Bieuvelet S, Burckel A et al. (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32, 147-152.
80. Simren M, Ohman L, Olsson J et al. (2010) Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-randomized, double-blind, controlled study. Aliment Pharmacol Ther 31, 218-227.
81. Sondergaard B, Olsson J, Ohlson K et al. (2011) Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 46, 663-672.
82. Ligaarden SC, Axelsson L, Naterstad K et al. (2010) A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 10, 16.
83. Bausserman M & Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147, 197-201.
84. Gawronska A, Dziechciarz P, Horvath A et al. (2007) A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 25, 177-184.
85. Francavilla R, Miniello V, Magista AM et al. (2010) A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126, 1445-1452.
86. Guandalini S, Magazzu G, Chiaro A et al. (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51, 24-30.
87. Houghton LA, Lea R, Agrawal A et al. (2006) Relationship of abdominal bloating to distension in irritable bowel syndrome and effect of bowel habit. Gastroenterology 131, 1003-1010.
88. Agrawal A, Houghton LA, Reilly B et al. (2009) Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 104, 1998-2004.